NABIHA FAISAL

• Canadian Association for the Study of the Liver (CASL)
• American Association of the Study of Liver Diseases (AASLD)
• European Association of the Study of the Liver (EASL)
• American College of Physicians (ACP)
• Canadian Medical Association
• Asia Pacific Association of the Study of the Liver (APSAL)
• Pakistan Society of Gastroenterology (PSG)

• Licentiate of the Medical Council of Canada, College of Physicians and Surgeons of Manitoba 2019
• College of Physicians and surgeons Manitoba September 2018 to Present
• College of Physicians and surgeons of Ontario, July 2012-June 2015
• Pakistan Medical and Dental Council, Specialist License, 2000 - Present

• 2022/3 Member, Scientific Planning Committee, Single Topic Conference on alcohol-associated liver disease, Canadian Association for the Study of the Liver
• 2022/1 Member, Guideline Committee, Alcohol-Associated Liver Disease in Canada. Canadian Association for the Study of the Liver in Canada
• 2021/5 Member, Search Committee, Immunocompromised Host, Section of Infectious Diseases,University of Manitoba
• 2020/12 Member, Diversity, Equity and Inclusion, Canadian Association of Study of Liver diseases
• 2020/6 Member, Executive committee, Pakistani Doctors of Manitoba

• 2023/09 Speaker, PBC Society Speaker Series. Radisson Hotel. Winnipeg, Manitoba.
• 2023/09 CPD Speaker, Thompson Community Based CPD Program. Manitoba
• 2023/2 Panel Speaker, Ethics, Diversity and Inclusion/Global Health Conference, University of Manitoba, Conference. Winnipeg, Manitoba
• 2023/3 Moderator, Joint Canadian Digestive Disease Week-Canadian Liver Meeting 2023, Conference, Halifax, Canada.
• 2023/6 Speaker, Canadian College of Medical Geneticist-Canadian Society of Clinical Chemists Joint Scientific Meeting, Fairmont Winnipeg, Manitoba.
• 2023/3 Co-chair CLM session: Liver Transplantation, Joint Canadian Digestive Disease Week-Canadian Liver Meeting 2023, Conference. Halifax, Canada.
• 2022/10 Moderator, Canadian Association for the Study of the Liver (CASL) Single Topic Conference on Alcohol Liver Disease, Conference. Vancouver, Canada.
• 2022/10 Speaker, Canadian Association for the Study of the Liver (CASL) Single Topic Conference on Alcohol Liver Disease, Conference. Vancouver, Canada.
• 2022/8 Speaker, Association of Physicians of Pakistani Decent of North America Western Canada Conference. Banff, Canada.
• 2022/1 Speaker, South Asian Student Association (SAMSA), Winnipeg, Canada.
• 2021/12 Speaker, 15th Pakistan Society of Study of Liver diseases (PSSLD) 2021 annual meeting. Quetta, Pakistan.
• 2021/10 Chair, Pakistan Society of Liver Cancer Seminar. Role of Liver Transplantation in Hepatocellular Carcinoma
• 2021/5 Moderator, Pakistani Doctors of Manitoba - Virtual Social Program. Winnipeg, Canada.
• 2019/6 Speaker, Pathways to Liver Transplantation & Living Organ Donation, Seminar. Winnipeg, Canada.

• Faisal N, Lix ML, et al. Cirrhosis incidence among young adults (18-44) and in Females - a population-based study from 2010 to 2019. Boston, AASLD 2023
• Global prevalence of infections and impact of regional variations on outcomes: Multi-national consortium of cirrhosis study. C.L.E.A.R.E.D Investigators, Boston AASLD 2023
• Van Iderstine M, Griggs B, Thorleifson O, Minuk GY and Faisal N. Predicting future decompensation in patients with cirrhosis: A machine learning approach to risk stratification at the first patient visit. Boston AASLD 2023.
• Private insurance access is associated with higher liver transplant listing and transplant access and lower mortality compared to national insurances in a large multi-national cohort of inpatients with cirrhosis. C.L.E.A.R.E.D Investigators, Boston AASLD 2023.
• Regional differences in acute kidney injury prevalence, clinical characteristics and patient outcomes in a multi-national consortium of inpatients with cirrhosis. C.L.E.A.R.E.D Investigators, Boston, AASLD 2023.
• Faisal N and Knight Erin. Who,what, where and why: Establishing an interdisciplinary group medical visit model fro alcohol associated liver disease. CSAM, Victoria 2023.
• Faisal N, Lix ML, et al. Identifying patients with diagnosed cirrhosis in administrative health databases: a validation study. CAHSPR, Montreal, Quebec May 2023.
• Minuk GY, Peretz D, Faisal N et al. Insulin Secretion in Liver Transplant Recipients Following Conversion to a Prolonged Release Tacrolimus Formulation. Joint International Congress of ILTS, ELITA and LICAGE, Amsterdam, Netherland May 2023.
• Faisal N, Kosowan L, et al. Development and validation of a case definition to estimate the prevalence and incidence of cirrhosis using a pan-Canadian primary care database. Canadian Association of Study of Liver disease Annual Meeting, March 2023, Halifax, Canada.
• Faisal N, Kosowan L, et.al. Identifying patients with cirrhosis in primary care clinics – development and validation of a case definition using electronic medical records. Family Medicine Forum 2022, Toronto, Canada.
• Low serum albumin at admission is associated with mortality among inpatients with cirrhosis: a multi-national experience. C.L.E.A.R.E.D Investigators. AASLD 2022
• CLEARED Differences in mortality rates in inpatients with cirrhosis depends on the low, middle or high income country location: multi-national cleared consortium experience. C.L.E.A.R.E.D Investigators. AASLD 2022
• CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease. C.L.E.A.R.E.D Investigators. EASL 2022
• Predicting prognosis in large cohort of Decompensated Cirrhosis of Liver (DCLD)- a Machine Learning (ML) approach. C.L.E.A.R.E.D Investigators. EASL 2022
• Faisal N, Virid P et al. Effect of probiotics on hepatic steatosis, inflammation and fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Canadian Society of Study of Liver Disease, CASL, July 2021
• Tse, C., Lisanti, N., Uhanova J, Minuk, G. Faisal, N Comparison of Different Definitions of Metabolic Syndrome and Association with Non-Alcoholic Fatty Liver Disease: A Retrospective Study. Canadian Association of Study of Liver disease Annual Meeting, July 2021.
• Singh, N, Faisal N and De Gussem EM. International HHT Challenging Case Series - Liver AVM. International HHT Clinical and Scientific Forum, August 2021.
• Faisal N, Renner EL, Bilodeau M et al. Impact of Sofosbuvir-Based Regimens on Renal Function in Liver Transplant Recipients: Results of a Multicenter Study. (Oral presentation AASLD November 13-17, 2015)
• Faisal N, Lilly LB.The Game has Indeed Been Changed: Results of a Nationwide Study on the Treatment of Recurrent HCV in Liver Transplantation. Sheila Sherlock Liver Research Day. May 28th, 2015, University of Toronto, Canada
• Faisal N, Lilly LB. Have We Achieved “NEAR-PERFECTOVIR”? Hepatobiliary Round May 19th, 2015, University of Toronto, Canada
• Faisal N, Bilodeau M, Yoshida EM, Ma MM, Renner EL. et al. Sofosbuvir based antiviral treatment is highly effective in recurrent HCV in liver transplant recipients: Canadian Real-world Multicenter Experience. EASL, Vienna, Austria. April 22-26, 2015
• Faisal N, Renner EL, Lilly LB. Protease Inhibitor-Based Triple Therapy Is Highly Effective In Liver Transplant Recipients with Genotype 1 Hepatitis C Recurrence: A Large Single Center Experience. 29th Annual Sheila Sherlock Liver Research Day. May 22th, 2014, University of Toronto, Canada
• Faisal N, Mumtaz K, Renner E, Lilly LB. Treatment with pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C post liver transplantation: western single center series. 29th Annual Sheila Sherlock Liver Research Day. May 22th, 2014, University of Toronto, Canada
• Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma MM, Renner EL. et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 Hepatitis C recurrence: a Canadian multicenter experience. (Oral presentation AASLD Nov 1-5 2013)
• Mumtaz K, Faisal N, Morillo A, Renner E. Universal prophylaxis or pre-emptive therapy in the prevention of cytomegalovirus (CMV) disease after liver transplantation (LT): A systematic review and meta-analysis. AASLD Nov 1-5 2013
• Faisal N, Mumtaz K, Renner E, Lilly LB. SVR rates of 71% following treatment with pegylated interferon and ribavirin for recurrent genotype 3 hepatitis c post liver transplantation: Retrospective analysis of a western single center series. AASLD Nov 1-5 2013
• Nazim A, Faisal N, Haq M. Hepatic encephalopathy in cirrhotic patients undergoing endoscopic examination using midazolam for sedation. UEGW, Stockholm, Oct 22-26 2011
• Faisal N, Esmail J. Is hepatitis C a stigma? Patient's perspective at a tertiary care center. Gold medal (Oral presentation) Annual Pakistan Society of Gastroenterology (PSG) meeting, 2009 in Lahore, Pakistan
• Faisal N, Esmail J, Sheikh H. Prevalence of H pylori infection at a tertiary care hospital. (Oral presentation) Annual Pakistan Society of Gastroenterology (PSG) meeting, 2009 in Lahore, Pakistan 2009
• Faisal N, Sheikh H, Esmail J. Knowledge and Misconception of hepatitis C patients. (Oral presentation) Annual Pakistan Society of Gastroenterology (PSG) meeting, 2008 in Quetta, Pakistan 2008
• Faisal N, Esmail J, Sheikh H.Mannan A. Awareness of Hepatitis C and B in paramedics: a hospital based study. Annual Pakistan Society of Gastroenterology (PSG) meeting, 2008 in Quetta, Pakistan 2008
• Faisal N, Sheikh H, Esmail J. Prevalence of Helicobacter pylori by rapid urease test on a single antral biopsy done in dyspeptic patients undergoing endoscopy; a retrospective analysis. Annual Pakistan Society of Gastroenterology (PSG) meeting, 2008 in Quetta, Pakistan 2008
• Faisal N, Zuberi BF. Correlation between clinical, endoscopic & histological findings at esophago-gastric junction in patients of gastro esophageal reflux disease. Annual Pakistan Society of Gastroenterology (PSG) meeting, 2005 in Quetta, Pakistan
• Faisal N, Sheikh Z. An Interesting Case of Hypoglycemia. Oral presentation in Dow Medical College Symposium 2004, Karachi Pakistan.

• American Association of Study of Liver Disease annual conference, Boston, 2023
• Canadian Society of Addiction Medicine, annual conference, Victoria, BC 2023.
• Canadian Association of Study of Liver Disease (CASL) annual conference, Montreal Feb 28- March 1, 2023
• Canadian Association of Study of Liver Disease (CASL) Single Topic conference: Alcohol Liver Disease Aug 2022
• European Association Study of Liver Disease (EASL) Conference, Amsterdam, April 19-23, 2017.
• Canadian Institutes of Health Research - Reviewer in Training Program, Canadian Institutes of Health Research, April 2021 - June 2021
• George & Fay Yee Centre for Healthcare Innovation (CHI) Rounds 2021/2022.
• Continuing Professional Development program, MCC 360, Medical Council of Canada Jan 2019- Feb 2020
• CASL conference, Montreal Feb 28th- March 1st, 2020
• Canadian Institutes of Health Research (CIHR) Institute of Nutrition, Metabolism and Diabetes (INMD) Early Career Investigator Meeting - November 2019
• Canadian Institutes of Health Research (CHIR) Institute of Gender and Health Core Competency Module for Sex and Gender in Biomedical Research.
• Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans Course on Research Ethics (TCPS 2:CORE), Panel on Research Ethics
• CASL CLF International Meeting on Non Alcoholic Fatty Liver Disease NAFLD. Winnipeg, Canada, Sep 9-11, 2017.
• EASL Conference, Postgraduate course. Amsterdam, April 19-23, 2017.
• Annual meeting of Saudi Association of study of Liver diseases. Feb 12-14 2017. Jeddah, Saudi Arabia
• Moderate Sedation Course. June 2016, Riyadh, Saudi Arabia.
• Saudi association of study of liver disease and liver transplantation conference, May 12-15th 2016, Madina. Saudi Arabia
• Qualitative Evidence Program by National and Gulf center for evidence based health practice, 25th – 27th April 2016. Riyadh. Saudi Arabia
• Clinical Trial Design and Statistics Principles. March 25-27 2016 Riyadh. Saudi Arabia.
• AASLD Post graduate and Transplant course, November 2015
• Hepatology Update. Toronto, Canada May 29th 2015
• EASL Conference, Transplant workshop, NAFLD workshop. Vienna, 2015.
• AASLD Conference, Boston, Nov 2014
• 3rd Canadian Symposium on Hepatitis C Virus, Feb 2014
• CASL Hepatocellular Carcinoma Meeting: Consensus, Controversies, and Future Directions, Feb 2014
• AASLD Post graduate Hepatology and Transplant course, Nov 2013
• Symposium “HCV From discovery to Cure” held in Toronto, Canada. Oct 2013
• Attended the “First hands-on ERCP training course” with the collaboration of Mersey School of Endoscopy Liverpool University Hospital, UK. Dec 12-15 2011
• Attended a Single Topic Conference on Hepatic Encephalopathy organized by World Gastroenterology Organization, held in 2011
• Delivered a lecture on “Screening, counseling and diagnosis of Hepatitis B” on “World Hepatitis Day” held in Karachi, July 2011
• Attended Pakistan Society of Gastroenterology regional meeting in Quetta, 2009 and presented different aspects of Hepatitis B and C
• Annual Pakistan Society for Study of Liver Disease” (PSSLD) from 29th November to 1st December, 2008 at Pearl Continental Hotel, Karachi. The meeting was well attended by the faculty and participants from all over Pakistan
• The 2nd meeting of “Portal Hypertension research group” on 12th October, 2008 at Sheraton Hotel Karachi. Eminent speakers from all over Pakistan attended this meeting and discussed the different protocols related to Portal Hypertension
• Moderated a full day seminar on World Diabetes Day conducted in Karachi, Pakistan, 2004.

• Faisal N, Lix LM, et al. Trends in the incidence and prevalence of cirrhosis in Manitoba, Canada: A population-based study (2010-2019). (Under review with Annals of Hepatology).
• Ragheb M, Iderstine MGV, Minuk GY and Faisal N. Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in non-alcoholic fatty liver disease (under review with Canadian Liver Journal).
• Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. The New England journal of medicine. 2023. Elative study Investigators.
• Faisal N, Lix, LM et al. Identifying patients with diagnosed cirrhosis in administrative health databases: a validation study. Canadian Liver Journal (In press).
• Tse C, Lisanti N, Iderstine MGV, Uhanova J, Minuk, G and Faisal N. Comparison of Different Definitions of Metabolic Syndrome and Association with Non-Alcoholic Fatty Liver Disease: A Retrospective Study. Can Liver J. 2023;6(4):395-406.
• Faisal N, Kosowan L, et al. Development and validation of a case definition to estimate the prevalence and incidence of cirrhosis in pan-Canadian primary care databases. Can Liver J. 2023;6(4):375-87.
• Global Disparities in Mortality and Liver Transplant in Hospitalized Patients with Cirrhosis: A Prospective Observational Study for the CLEARED Consortium. C.L.E.A.R.E.D Investigators. Lancet Gastroenterol Hepatol. 2023;8(7):611-22.
• Peretz D, Faisal N et al. Insulin Secretion in Liver Transplant Recipients Following Conversion to a Prolonged Release Tacrolimus Formulation. Canadian Liver Journal, 2023;6(3):353-7.
• Dascal R, Wiebe C, Niazi M, Worobetz L, Bhanji RA, Knowles C, Uhanova J, Peretz P, Faisal N, Minuk GY. Post-transplant diabetes mellitus in Canadian liver and renal transplant recipients. Canadian Liver Journal, 2022.
• Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Lilly LB.Exp Clin Transplant. 2019 Apr 4. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
• Faisal N. Hepatitis C and liver transplantation in direct acting antiviral era. AME Med J 2018;3:40.
• Aljumah AA, Kuriry H, Faisal N, Alghamdi H.Ann Saudi Med. 2018 Sep-Oct;38(5):358-365. Clinicopathologic characteristics and outcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.
• Faisal N, Bilodeau M, Yoshida EM, Ma MM, Renner EL. et al. Sofosbuvir based antiviral treatment is highly effective in recurrent HCV in liver transplant recipients: Canadian Real-world Multicenter Experience. "Transplantation" 2016, May 100(5) 1059-65.
• Faisal N, Renner EL. Recurrent autoimmune liver diseases after liver transplantation. World journal of Hepatology, December 2015.
• Mumtaz K, Faisal N, Renner EL et al. Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-center experience of over 1000 liver transplantations. Canadian Journal of Gastroenterology & Hepatology June 2015.
• Mumtaz K, Faisal N, Morillo A, Renner E, Husain S. Universal prophylaxis or pre-emptive therapy in the prevention of cytomegalovirus disease after liver transplantation: A systematic review and meta- analysis. Am J Transplant. 2015 Feb;15(2):472-81
• Faisal N, Mumtaz K, Renner E, Lilly LB. SVR rates of 71% following treatment with pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C post liver transplantation: Retrospective analysis of a western single center series. Hepatol Int. 2015 Jan;9(1)76-83.
• Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma MM, Burak K, Renner E, et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 Hepatitis C recurrence: a Canadian multicenter experience. Annals of Heptology. 2014;13(5):525- 32.
• Haq MM, Faisal N, Khalil A, Haqqi SA, Shaikh H, Arain N. Midazolam for sedation during diagnostic or therapeutic upper gastrointestinal endoscopy in cirrhotic patients. Eur J Gastroenterol Hepatol. 2012 Oct; 24(10):1214-8.
• Kamani L, Mahmood S, Faisal N. Therapeutic endoscopic retrograde cholangiopancreatography without ultrasound or fluoroscopy in pregnancy. Endoscopy. 2012;44 Suppl 2 UCTN:E196. doi: 10.1055/s- 0031-1291761. Epub 2012 May 23.
• Faisal N, Haq M, Shaikh H, Ashraf P, Esmail, JH. Helicobacter pylori infection; dyspeptic patients undergoing endoscopy: a hospital based study. Professional Med. J. - Q 2012. 19 (2): 202-7
• Haq M, Faisal N. Familial Adenomatous Polyposis Syndrome, a case report. JCPSP. 2011; 21 (1): 46-8
• Ashraf P, Shah M, Shaikh H, Faisal N. Portal Hypertensive Gastropathy undergoing TIPS: a case report. JCPSP. 2009; 19 (9): 584-5
• Zuberi BF; Zuberi FF; Vasvani A; Faisal N; Afsar S; Rehman J; et al. Appraisal of the knowledge of Internet users of Pakistan regarding hepatitis using on-line survey. Journal of Ayub Medical College, Abbottabad : JAMC 2008;20(1):91-3.
• Zuberi BF; Ahmed S; Faisal N; Afsar S; Memon AR; Baloch I; et al. Comparison of heart rate and QTc duration in patients of cirrhosis of liver with non-cirrhotic controls. Journal of the College of Physicians and Surgeons Pakistan: JCPSP 2007; 17(2):69-71.
• Zuberi BF; Faisal N; Quraishy MS; Afsar S; Kazi LG; Kazim E. Correlation between clinical endoscopic and histological findings at esophago-gastric junction in patients of gastroesophageal reflux disease. Journal of the College of Physicians and SurgeonsPakistan: JCPSP 2005; 15(12):774-7.
• Zuberi BF; Quraishy MS; Faisal N; Ahmed S. Idiopathic gastroparesis. Journal of the College of Physicians and Surgeons Pakistan: JCPSP 2005; 15(9):566-7.

• EASL Bursary

Sofosbuvir based antiviral treatment is highly effective in recurrent HCV in liver transplant recipients: Canadian Real-world Multicenter Experience. European Association of Study of Liver disease (EASL), 2015 Vienna, Austria

• Chief Fellow - Transplant Hepatology, University of Toronto 2014-15
• Gold Medal

Is hepatitis C a stigma? Patient's perspective at a tertiary care center. Pakistan Society of Gastroenterology Conference, 2009 in Lahore, Pakistan.

• Chief Resident - 2007-08

 Awarded – Active
2023/10/15-2025/Health Science Centre Foundation10/15
Principal Investigator
Title: A Feasibility Study of Integrating and Improving Care of Co morbid Alcohol Use Disorder and Alcohol Liver Disease.
Agency: Health Science Centre Foundation General Operating Grant
Budget: $69,500 CAD

Awarded - Completed

2021 - Mitacs Accelerate Research Award

Title: Developing and validating PTSD, Veterans and Families of Military

Agency: IBM

Budget: $10,000 CAD

• Quality Improvement Projects: Hepatology ambulatory work flow
• Peer Reviewer, Transplantation, Journal of the Canadian Association of Gastroenterology, Canadian Medical Association Journal.
• Reviewer/Poster judge, Resident Research Day, Nov 2022
• Site PI - Participation in CLEARED Global Consortium
• Site PI - Canadian Network for Autoimmune Liver disease (CaNAL)
• Site PI - CanGIEC PSC-IBD Project
• Site PI - Canadian HepB Network study
• Site PI - Genfit Elative PBC study
• Industry collaboration: Scientific Exchange Meeting with Advanz and Paladin.